Modality
mRNA
MOA
KRASG12Di
Target
Menin
Pathway
Angiogenesis
CLL
Development Pipeline
Preclinical
Apr 2017
→ Feb 2030
PreclinicalCurrent
NCT08338462
571 pts·CLL
2017-04→2030-02·Not yet recruiting
571 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-02-193.9y awayInterim· CLL
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Preclinical
Not yet…
Catalysts
Interim
2030-02-19 · 3.9y away
CLL
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08338462 | Preclinical | CLL | Not yet recr... | 571 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα | |
| Cevimavacamten | Denali | NDA/BLA | Menin |